CR
Therapeutic Areas
Corcept Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Korlym® (mifepristone) | Hypercortisolism (Cushing Syndrome) | Approved |
| Relacorilant | Hypercortisolism (Cushing Syndrome) - GRACE study | Phase 3 |
| Relacorilant + Nab-paclitaxel | Platinum-resistant ovarian cancer - ROSELLA study | Phase 3 |
| Relacorilant + Nab-paclitaxel + Bevacizumab | Platinum-resistant ovarian cancer - BELLA Arm A | Phase 2 |
| Relacorilant + Nab-paclitaxel + Gemcitabine | Pancreatic cancer - TRIDENT study | Phase 2 |
| Nenocorilant + Nivolumab | Solid tumors - SYNERGY study | Phase 2 |
| Relacorilant + Enzalutamide | Prostate cancer | Phase 2 |
| Dazucorilant | Amyotrophic Lateral Sclerosis (ALS) - DAZALS study | Phase 2 |
Leadership Team at Corcept Therapeutics
JK
Joseph K. Belanoff
Chief Executive Officer, President and Director
AF
Amy Flood
Chief Human Resources and Communications Officer
WG
William Guyer
Chief Development Officer
HH
Hazel Hunt
Chief Scientific Officer
JL
J.D. Lyon
Chief Accounting and Technology Officer
SM
Sean Maduck
President, Endocrinology
AM
Atabak Mokari
Chief Financial Officer
MT
Monica Tellado
President, Emerging Markets
RV
Roberto Vieira
President, Oncology
JN
James N. Wilson
Chairman of the Board